drugset / Trial / NCT03580005

A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.

NCT03580005

Phase 4 Withdrawn Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A 6-week double-blind study to evaluate the safety and efficacy of Quillichew extended release chewable tablets in 4-5 year old children with attention deficit hyperactivity disorder.

Timeline

Start
2018-10-31
Primary completion
2021-10-12
Completion
2021-10-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule